Register Login

ProKidney Corp (PROK)

(10% Negative) ProKidney Corp (PROK) Announces Delay in pathway Trials for rilparencel Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:31 p.m.

    📋 ProKidney Corp (PROK) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:54:17

    Event Type: Clinical Trial Update

    Event Details:

    ProKidney Corp (PROK) Announces Clinical Trial Update ProKidney Corp (PROK) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: pathway, Function
    • Diseases/Conditions: rilparencel
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Company
      • expected in Q2 2027
      • anticipated in Q2 2027

    🔬 Clinical Development Pipeline (ProKidney Corp):

    Product Type Development Stage Therapeutic Area Source
    Renal Autologous Cell Therapy (REACT) BIOLOGICAL Phase PHASE3 Type 2 Diabetes Mellitus ClinicalTrials.gov
    Sham Comparator PROCEDURE Phase PHASE3 Type 2 Diabetes Mellitus ClinicalTrials.gov
    Neo-Kidney Augment BIOLOGICAL Phase PHASE2 Chronic Kidney Disease ClinicalTrials.gov
    Renal Biopsy PROCEDURE Phase PHASE2 Type 2 Diabetes Mellitus ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ProKidney Corp
    • Ticker Symbol: PROK

Search

News categories